Euractiv (Partner Content)
EU Perspectives
European Biotechnology Magazine
APM Market Access
EU PERSPECTIVES - Fall ill on holiday in another EU country, and the bill is yours to pay first. Patients then wait an average of 69 days to get their money back from home. Lawmakers now want member states to settle up between themselves instead, so patients never have to pay at all. Read more
EURACTIV - UCB is the only company headquartered in the European Union among the nine drugmakers that signed Donald Trump's most-favoured-nation pricing plan on Monday, 31 August. Its new US factory will not come at Europe's expense, the Brussels-based company said. Read more
EU PERSPECTIVES - It can save young lives but it is not attractive enough for investors. That is the cruel economics of childhood cancer treatment. Léonor, a ten-year-old cancer survivor, asks Europe to change that. Read more
EU PERSPECTIVES - Europe's top life sciences investors have welcomed the EU's new €5bn Scaleup Europe Fund. One of its own backers, Novo Holdings, has just put €500m into it. Yet the same investors told EU Perspectives the fund will barely touch their sector's real funding problem. Read more
